The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans

被引:61
作者
van der Meer, Anne J. [1 ]
Scicluna, Brendon P. [1 ]
Moerland, Perry D. [2 ]
Lin, Jiang [3 ]
Jacobson, Eric W. [4 ]
Vlasuk, George P. [4 ]
van der Poll, Tom [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, CEMM, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol, Bioinformat Lab, NL-1105 AZ Amsterdam, Netherlands
[3] GlaxoSmithKline, Durham, NC USA
[4] Sirtris, Cambridge, MA USA
关键词
sirtuin; 1; blood coagulation; clinical trial; endotoxemia; inflammation; pharmaceutical preparations; INFLAMMATION;
D O I
10.1097/CCM.0000000000000949
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Objectives: Sirtuin 1 influences gene expression and other cellular functions through deacetylation of histone and nonhistone proteins. We here sought to determine the effects of a small molecule sirtuin 1 activator, SRT2104, on inflammation and coagulation induced by lipopolysaccharide in humans. Design: A randomized, double-blind, placebo-controlled study. Setting: An academic hospital. Subjects: Twenty-four healthy humans. Interventions: All subjects received an intravenous injection with lipopolysaccharide. Subjects were randomized to one of three groups (n = 8 per group): 1) pretreatment with oral SRT2104 for 7 days (2 g/d), 2) pretreatment with a single SRT2104 dose (2 g), or 3) placebo. Measurements and Main Results: SRT2104 attenuated lipopolysaccharide-induced release of the cytokines interleukin-6 (mean peak levels of 58.8% [p < 0.05] and 80.9% [p = 0.078] after single and repeated SRT2104 administration, respectively, relative to those measured after placebo treatment) and interleukin-8 (mean peak levels of 57.0% [p < 0.05 vs placebo] and 77.1% [p < 0.05 vs placebo] after single and repeated SRT2104 ingestion, respectively, while not affecting tumor necrosis factor-a and interleukin-10 release). SRT2104 also reduced the lipopolysaccharide-induced acute phase protein response (C-reactive protein). SRT2104 inhibited activation of coagulation, as reflected by lower plasma levels of the prothrombin fragment F1 + 2 (mean peak levels 57.9% [p < 0.05] and 64.2% [p < 0.05] after single and repeated SRT2104 administration, respectively, relative to those measured after placebo treatment). Activation of the vascular endothelium (plasma von Willebrand levels) and the fibrinolytic system (plasma tissue-type plasminogen activator and plasminogen activator inhibitor type I) was not influenced by SRT2104. Conclusions: This is the first human study to demonstrate biological anti-inflammatory and anticoagulant responses consistent with the activation of sirtuin 1 by a small molecule.
引用
收藏
页码:E199 / E202
页数:4
相关论文
共 10 条
[1]
Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells [J].
Breitenstein, Alexander ;
Stein, Sokrates ;
Holy, Erik W. ;
Camici, Giovanni G. ;
Lohmann, Christine ;
Akhmedov, Alexander ;
Spescha, Remo ;
Elliott, Peter J. ;
Westphal, Christoph H. ;
Matter, Christian M. ;
Luescher, Thomas F. ;
Tanner, Felix C. .
CARDIOVASCULAR RESEARCH, 2011, 89 (02) :464-472
[2]
A network-based analysis of systemic inflammation in humans [J].
Calvano, SE ;
Xiao, WZ ;
Richards, DR ;
Felciano, RM ;
Baker, HV ;
Cho, RJ ;
Chen, RO ;
Brownstein, BH ;
Cobb, JP ;
Tschoeke, SK ;
Miller-Graziano, C ;
Moldawer, LL ;
Mindrinos, MN ;
Davis, RW ;
Tompkins, RG ;
Lowry, SF .
NATURE, 2005, 437 (7061) :1032-1037
[3]
Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia [J].
de Jonge, E ;
Dekkers, PEP ;
Creasey, AA ;
Hack, CE ;
Paulson, SK ;
Karim, A ;
Kesecioglu, J ;
Levi, M ;
van Deventer, SJH ;
van der Poll, T .
BLOOD, 2000, 95 (04) :1124-1129
[4]
Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man [J].
Hoffmann, Ethan ;
Wald, Jeff ;
Lavu, Siva ;
Roberts, John ;
Beaumont, Claire ;
Haddad, Jon ;
Elliott, Peter ;
Westphal, Christoph ;
Jacobson, Eric .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) :186-196
[5]
Sirtuins and the circadian clock: Bridging chromatin and metabolism [J].
Masri, Selma ;
Sassone-Corsi, Paolo .
SCIENCE SIGNALING, 2014, 7 (342)
[6]
SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass [J].
Mercken, Evi M. ;
Mitchell, Sarah J. ;
Martin-Montalvo, Alejandro ;
Minor, Robin K. ;
Almeida, Maria ;
Gomes, Ana P. ;
Scheibye-Knudsen, Morten ;
Palacios, Hector H. ;
Licata, Jordan J. ;
Zhang, Yongqing ;
Becker, Kevin G. ;
Khraiwesh, Husam ;
Gonzalez-Reyes, Jose A. ;
Villalba, Jose M. ;
Baur, Joseph A. ;
Elliott, Peter ;
Westphal, Christoph ;
Vlasuk, George P. ;
Ellis, James L. ;
Sinclair, David A. ;
Bernier, Michel ;
de Cabo, Rafael .
AGING CELL, 2014, 13 (05) :787-796
[7]
Ng PY, 2013, LETT DRUG DES DISCOV, V10, P793
[8]
Negative regulation of inflammation by SIRT1 [J].
Xie, Jun ;
Zhang, Xiaoming ;
Zhang, Li .
PHARMACOLOGICAL RESEARCH, 2013, 67 (01) :60-67
[9]
Identification of IGF1, SLC4A4, WWOX, and SFMBT1 as Hypertension Susceptibility Genes in Han Chinese with a Genome-Wide Gene-Based Association Study [J].
Yang, Hsin-Chou ;
Liang, Yu-Jen ;
Chen, Jaw-Wen ;
Chiang, Kuang-Mao ;
Chung, Chia-Min ;
Ho, Hung-Yun ;
Ting, Chih-Tai ;
Lin, Tsung-Hsien ;
Sheu, Sheng-Hsiung ;
Tsai, Wei-Chuan ;
Chen, Jyh-Hong ;
Leu, Hsin-Bang ;
Yin, Wei-Hsian ;
Chiu, Ting-Yu ;
Chern, Ching-Iuan ;
Lin, Shing-Jong ;
Tomlinson, Brian ;
Guo, Youling ;
Sham, Pak C. ;
Cherny, Stacey S. ;
Lam, Tai Hing ;
Thomas, Neil ;
Pan, Wen-Harn .
PLOS ONE, 2012, 7 (03)
[10]
Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice [J].
Zhang, Qing-jun ;
Wang, Zhao ;
Chen, Hou-Zao ;
Zhou, Shuang ;
Zheng, Wei ;
Liu, Guang ;
Wei, Yu-sheng ;
Cai, Hua ;
Liu, De-pei ;
Liang, Chih-chuan .
CARDIOVASCULAR RESEARCH, 2008, 80 (02) :191-199